Haleon PLC has been steadfast in implementing its share
buyback strategy, with several successful executions reported. This execution has been greeted with varying investor reactions as shown in the company's fluctuating stock prices, reaching both 1-year highs and nearing the end of corrections.
Pfizer and
GSK both indicated their plans to reduce stakes in Haleon, with GSK intending to divest its remaining 4.2% stake in the company and Pfizer selling off its £3 Billion stake. These sell-offs were concurrent with Haleon purchasing shares, contributing to its buyback strategy. The company posted notable growth in its
Interim Dividend for 2024, and showed promise as a defensive consumer healthcare stock. Haleon's robust performance has been attributed to investment in its brand and reduced debt. The corporation has further diversified its portfolio by divesting the ChapStick brand and intending to acquire nicotine addiction treatment from Dr. Reddy's. Despite its repositioning initiatives, Goldman Sachs downgraded Haleon to 'Neutral', citing overvaluation.
Haleon Stocks News Analytics from Thu, 05 Oct 2023 07:00:00 GMT to Sun, 08 Sep 2024 11:10:29 GMT -
Rating 8
- Innovation 5
- Information 8
- Rumor -2
